Answers are grounded in this paper and cite their sources.
Pro-fibrotic M2-like macrophages are widely implicated in the pathogenesis and progression of lung fibrosis due to their production of pro-fibrotic growth factors and cytokines. Yeast beta-glucan (YBG) microparticles have shown potential as immunomodulators that can convert macrophage polarization from a pro-fibrotic phenotype to an anti-fibrotic phenotype through the engagement of the Dectin-1 receptor. However, the processing conditions used to fabricate YBG microparticles can lead to unpredictable immunomodulatory effects. Herein, we report the use of Pressurized Gas eXpanded liquids (PGX) Technology® to fabricate YBG (PGX-YBG) microparticles with higher surface areas, lower densities, and smaller and more uniform size distributions compared to commercially available spray-dried YBGs. PGX-YBG is shown to activate Dectin-1 more efficiently in vitro while avoiding significant TLR 2/4 activation. Furthermore, PGX-YBG microparticles effectively modulate M2-like fibrosis-inducing murine and human macrophages into fibrosis-suppressing macrophages both in vitro as well as in ex vivo precision-cut murine lung slices, suggesting their potential utility as a therapeutic for addressing a broad spectrum of fibrotic end-point lung diseases. • Scalable production of high purity, highly porous yeast beta-glucan (PGX-YBG) microparticles. • Enhanced Dectin-1 activation compared to conventional spray dried YBG. • PGX-YBG preferentially taken up by pro-fibrotic macrophages. • Effective immunomodulation of human and murine macrophages in vitro and ex vivo . • Particle properties are conducive to effective lung delivery via inhalation.
No takes yet. Share an insight, caveat, or question.
Naiel et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: